Ranibizumab to Treat Type 2 Idiopathic Macular Telangiectasia (RAMA-Trial)
- Sponsor
- University Hospital, Bonn
- Study ID
- NCT00504400
- Phase
- PHASE2
- Status
- Completed
Conditions
- Type 2 Idiopathic Macular Telangiectasia
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Intravitreal injection ranibizumab — DRUGMonthly intravitreal injection of of 0.5mg ranibizumab in one eye over one year
Study Details
The purpose of this study is to investigate if a new drug called ranibizumab is effective to treat a rare bilateral disease of the macula: type 2 idiopathic macular telangiectasia (type 2 IMT). 10 patients will receive monthly injections of the drug into one eye over a period of one year.
Key Dates
- First listed
- Jul 20, 2007
- Start date
- Aug 31, 2007
- Status verified
- Sep 2009
- Primary completion
- Jun 30, 2009
- Completion
- Sep 30, 2009
Study Design
- Enrollment
- 10 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: A
Primary Outcome Measure
Best corrected visual acuity [ Time Frame: one year ]